Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells

Cancer Research

Volumn 66, Issue 1, 2006, Pages 46-51

  Yang, Anthony D ^a   Camp, E Ramsay ^a   Fan, Fan ^a   Shen, Lanlan ^a   Gray, Michael J ^a   Liu, Wenbiao ^a   Somcio, Ray ^a   Bauer, Todd W ^a   Wu, Yan ^b   Hicklin, Daniel J ^b   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA CATENIN; BLOCKING ANTIBODY; LIGAND; PLAKOGLOBIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 1 BLOCKER; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL MEMBRANE; CELL MOTILITY; CELL NUCLEUS; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; PSEUDOPODIUM; TUMOR GROWTH; WESTERN BLOTTING;

CELL LINE, TUMOR; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MESODERM; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 31544463515     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3086     Document Type: Article

References (22)

1. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
2. Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005; 104:427-38.
3. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24: 2647-53.
4. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
5. Elliott BE, Hung WL, Boag AH, et al. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 2002;80:91-102.
6. Thiery JP, Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 1999;18:31-42.
7. Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Current biology: CB 2003;13:1721-7.
8. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol 1995;269:G467-75.
9. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
10. Behrens J, von Kries JP, Kühl M, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
11. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002;3: 155-66.
12. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
13. Menke A, Philippi C, Vogelmann R, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 2001;61:3508-17.
14. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor {β}1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001;61:4222-8.
15. Graff JR, Greenberg VE, Herman JG, et al. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 1998;58: 2063-6.
16. Hsu MY, Wheelock MJ, Johnson KR, et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996;1: 188-94.
17. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
18. Scheumman GF, Hoang-Vu C, Cetin Y, et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 1995;80: 2168-72.
19. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with Fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Am J Clin Oncol 2005;23:3502-8.
20. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003;3:263-76.
21. Kindler HL, Friberg G, Stadier WM, et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium. In: ASCO 2004. San Francisco, CA: Gastrointestinal Cancers Symposium; 2004.
22. Seidel B, Braeg S, Adler G, et al. E- and N-cadherin differ with respect to their associated p120ctn isoforms and their ability to suppress invasive growth in pancreatic cancer cells. Oncogene 2004;23:5532-42.